Allogenic Stromal Vascular Fraction (SVF) therapy for Type 2 Diabetes Mellitus (T2DM): Case study

Abstracto

Pei Swam Ng

Introduction

T2DM is a common chronic metabolic disease which is increasing all over the world. Currently, there is no

known cure but the disease can only be controlled to improve the quality of life.

Objective

To investigate the potential of Stromal Vascular Fraction (SVF) for glycaemic control in T2DM patients.

Background

55 years old gentleman with underlying T2DM since year 2009 and was started on oral anti-diabetic (OAD)

agents for the past 10 years. In view of his poor glycaemic control despite on optimal conventional

medications, he consented to undergo Allogenic SVF therapy.

Method

Careful preparation measures were taken including proper selection of donor through screening. SVF cells

isolated and prepared in sterile setting. The patient underwent 3 sessions of Allogenic SVF therapy started

in Oct 2018, followed by Mar 2019 and June 2019. Each of the sessions, patient received 30ml SVF derived

from 50ml condensed adipose tissue (approximately 50-100,000 MSC per ml of adipose tissue) by

intravenous injection.

Result

Follow up was carried out 1 month after each session of Allogenic SVF therapy. Fasting glucose reduced

from 12.4mmol/L to 7.6mmol/L and HbA1c reduced from 7.6% to 6.9%. Patient’s OAD agent dosage

adjusted and no complication was observed.

Conclusion

We demonstrated the safety administration of intravenous Allogenic SVF. Despite conventional treatment,

we hope to encourage more SVF research for glycaemic control in T2DM and develop an effective stem-cell

based treatment for diabetes.